---
document_datetime: 2024-07-10 17:40:27
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/fruzaqla-epar-all-authorised-presentations_en.pdf
document_name: fruzaqla-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.6951988
conversion_datetime: 2025-12-20 13:59:12.241483
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| EU Number                         | (Invented) name   | Strength   | Pharmaceutical Form         | Route of Administration   | Immediate Packaging         | Pack size               |
|-----------------------------------|-------------------|------------|-----------------------------|---------------------------|-----------------------------|-------------------------|
| EU/1/24/1827/001 EU/1/24/1827/002 | FRUZAQLA FRUZAQLA | 1 mg 5 mg  | Capsule, hard Capsule, hard | Oral use Oral use         | bottle (HDPE) bottle (HDPE) | 21 capsules 21 capsules |